Asthma-related inflammation promotes lung metastasis of breast cancer cells through CCL11-CCR3 pathway.
Asthma
Breast cancer
CCL11–CCR3
Lung inflammation
Lung metastasis
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
19 Feb 2021
19 Feb 2021
Historique:
received:
29
10
2020
accepted:
07
02
2021
entrez:
20
2
2021
pubmed:
21
2
2021
medline:
5
11
2021
Statut:
epublish
Résumé
Mechanisms that preclude lung metastasis are still barely understood. The possible consequences of allergic airways inflammation on cancer dissemination were studied in a mouse model of breast cancer. Balb/c mice were immunized and daily exposed to ovalbumin (OVA) from day 21. They were subcutaneously injected with 4T1 mammary tumor cells on day 45 and sacrificed on day 67. Lung metastases were measured by biophotonic imaging (IVIS® 200 Imaging System) and histological measurement of tumor area (Cytomine software). Effects of CCL11 were assessed in vivo by intratracheal instillations of recCCL11 and in vitro using Boyden chambers. CCR3 expression on cell surface was assessed by flow cytometry. The extent of tumor metastases was significantly higher in lungs of OVA-exposed mice and increased levels of CCL11 expression were measured after OVA exposure. Migration of 4T1 cells and neutrophils was stimulated in vitro and in vivo by recCCL11. 4T1 cells and neutrophils express CCR3 as shown by flow cytometry and a selective CCR3 antagonist (SB-297006) inhibited the induction of 4T1 cells migration and proliferation in response to recCCL11. Allergic inflammation generated by exposure to allergens triggers the implantation of metastatic cells from primary breast tumor into lung tissues plausibly in a CCL11-CCR3-dependent manner. This indicates that asthma related inflammation in lungs might be a risk factor for lung metastasis in breast cancer patients.
Sections du résumé
BACKGROUND
BACKGROUND
Mechanisms that preclude lung metastasis are still barely understood. The possible consequences of allergic airways inflammation on cancer dissemination were studied in a mouse model of breast cancer.
METHODS
METHODS
Balb/c mice were immunized and daily exposed to ovalbumin (OVA) from day 21. They were subcutaneously injected with 4T1 mammary tumor cells on day 45 and sacrificed on day 67. Lung metastases were measured by biophotonic imaging (IVIS® 200 Imaging System) and histological measurement of tumor area (Cytomine software). Effects of CCL11 were assessed in vivo by intratracheal instillations of recCCL11 and in vitro using Boyden chambers. CCR3 expression on cell surface was assessed by flow cytometry.
RESULTS
RESULTS
The extent of tumor metastases was significantly higher in lungs of OVA-exposed mice and increased levels of CCL11 expression were measured after OVA exposure. Migration of 4T1 cells and neutrophils was stimulated in vitro and in vivo by recCCL11. 4T1 cells and neutrophils express CCR3 as shown by flow cytometry and a selective CCR3 antagonist (SB-297006) inhibited the induction of 4T1 cells migration and proliferation in response to recCCL11.
CONCLUSIONS
CONCLUSIONS
Allergic inflammation generated by exposure to allergens triggers the implantation of metastatic cells from primary breast tumor into lung tissues plausibly in a CCL11-CCR3-dependent manner. This indicates that asthma related inflammation in lungs might be a risk factor for lung metastasis in breast cancer patients.
Identifiants
pubmed: 33608009
doi: 10.1186/s12931-021-01652-9
pii: 10.1186/s12931-021-01652-9
pmc: PMC7893955
doi:
Substances chimiques
Ccl11 protein, mouse
0
Ccr3 protein, mouse
0
Chemokine CCL11
0
Receptors, CCR3
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61Subventions
Organisme : Fonds De La Recherche Scientifique - FNRS
ID : 7463012F
Références
Nat Med. 1996 Apr;2(4):449-56
pubmed: 8597956
Nat Immunol. 2015 Jun;16(6):609-17
pubmed: 25915731
Immunity. 2019 Feb 19;50(2):378-389.e5
pubmed: 30784579
Clin Cancer Res. 2009 Apr 15;15(8):2647-56
pubmed: 19351767
Oncotarget. 2016 May 31;7(22):32617-27
pubmed: 27119233
Cancer Res. 2008 Oct 15;68(20):8582-9
pubmed: 18922934
Leukemia. 2012 Oct;26(10):2269-76
pubmed: 22430634
J Biol Chem. 2014 Apr 25;289(17):12126-44
pubmed: 24619412
Allergy Asthma Immunol Res. 2017 Jul;9(4):360-367
pubmed: 28497923
Clin Cancer Res. 2012 Aug 15;18(16):4365-74
pubmed: 22711708
Curr Allergy Asthma Rep. 2005 Mar;5(2):155-60
pubmed: 15683617
J Immunol. 2002 Sep 1;169(5):2712-8
pubmed: 12193745
Thorax. 2019 Aug;74(8):768-779
pubmed: 31142617
Allergy. 2004 May;59(5):469-78
pubmed: 15080825
Int J Epidemiol. 1993 Dec;22(6):976-82
pubmed: 8144310
Carcinogenesis. 2012 Mar;33(3):587-97
pubmed: 22198214
Clin Cancer Res. 2005 Apr 1;11(7):2459-65
pubmed: 15814620
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Biol Chem. 2000 Nov 24;275(47):36626-31
pubmed: 10969084
Cell Cycle. 2009 Oct 15;8(20):3267-73
pubmed: 19770594
Front Pharmacol. 2017 Apr 18;8:207
pubmed: 28458639
Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1395-1403
pubmed: 31167755
Allergy Rhinol (Providence). 2019 Jul 22;10:2152656719860820
pubmed: 31384488
Oncotarget. 2017 Aug 1;8(45):79809-79815
pubmed: 29108362
Clin Transl Oncol. 2011 Oct;13(10):728-30
pubmed: 21975334
Stem Cell Res Ther. 2017 Feb 7;8(1):26
pubmed: 28173860
Cancer Growth Metastasis. 2017 Dec 21;10:1179064417745539
pubmed: 29308014
Oncotarget. 2017 Feb 14;8(7):11614-11620
pubmed: 28086224
Clin Exp Allergy. 2012 May;42(5):706-11
pubmed: 22515391
Cancer Growth Metastasis. 2017 Oct 27;10:1179064417738513
pubmed: 29123422
Blood. 2008 Jan 1;111(1):219-28
pubmed: 17885078
Prostate. 2015 Dec;75(16):1904-9
pubmed: 26306920
Am J Respir Crit Care Med. 2017 May 15;195(10):1321-1332
pubmed: 27922744
J Clin Invest. 2004 Nov;114(9):1317-25
pubmed: 15520864